Sonnet BioTherapeutics Holdings ( (SONN) ) has issued an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Sonnet BioTherapeutics Holdings, Inc. has partnered with Alkem Laboratories Limited to advance the development and commercialization of SON-080, a treatment for diabetic peripheral neuropathy (DPN) in India. This collaboration includes an upfront payment of $1 million to Sonnet, with the potential for an additional $1 million based on developmental milestones. Moreover, Sonnet will receive royalties from the net sales of the product. Alkem will handle clinical trials and regulatory processes in India, with Sonnet retaining the right to use the clinical data for partnerships outside India. The deal taps into a growing Indian market for DPN treatments, which is expected to more than double by 2030.
For a thorough assessment of SONN stock, go to TipRanks’ Stock Analysis page.
